ICH Q1 Stability Testing Overhaul: Preparing Your Programme for One Consolidated Guideline

For more than two decades, stability programmes have been designed around a patchwork of ICH guidelines: Q1A(R2) to Q1E and, for biologicals, Q5C. The draft ICH Q1 guideline replaces them with a single, consolidated text. According to the ICH Expert Working Group work plan, final adoption (Step 4) is planned for November 2026, so the time to review your stability strategy is now.

What is changing

The draft, endorsed at Step 2 by the ICH Assembly in April 2025, brings synthetic molecules, biologicals, vaccines and advanced therapy medicinal products under one core document with annexes. The ICH work plan also records a change of title to “Stability Testing of Drug Substances and Drug Products”. The structure is intended to be more consistent and more explicitly lifecycle-oriented, aligned with ICH Q8 to Q12.

The core principles will feel familiar: long-term, intermediate and accelerated storage conditions remain central. The difference lies in how clearly the guideline expects each choice to be justified.

Where the practical impact lies

  • Reduced designs. Bracketing and matrixing move into a dedicated annex. Expect reviewers to ask for a sound scientific rationale, not a design adopted by habit.
  • Statistical modelling and extrapolation. Shelf-life proposals based on modelling will need documented statistical reasoning and a clear link to the data.
  • Advanced therapies and biologicals. Stability expectations that previously sat in separate documents are now addressed together, which matters for companies working across modalities.
  • Lifecycle thinking. Stability data are positioned as supporting post-approval changes and shelf-life management, not only the initial dossier.

Why it matters for Greece and the EU

Once finalised, the guideline will be implemented in the EU through EMA, and EU-based applicants will be expected to follow it in marketing authorisation applications and variations submitted to EOF and the EMA. Studies started now may well be assessed against the final text, so protocols written today should not depend on assumptions the new guideline is likely to challenge. Note that the draft may still change before adoption, so always check the current status on the ICH and EMA websites.

A sensible preparation checklist

  • Compare the published draft with the guidelines cited in your current stability SOPs and protocol templates.
  • Inventory ongoing and planned studies, and flag those that rely on reduced designs or extrapolation.
  • Document the statistical and scientific justification for each reduced design and proposed shelf life.
  • Confirm that storage conditions and climatic zone coverage match your target markets.
  • Link stability commitments to your post-approval change strategy and variations planning.

How PQRA helps

PQRA supports pharmaceutical companies in Greece and the EU with regulatory strategy, dossier and CMC review, variations and lifecycle planning, and quality system alignment. We can help you assess your current stability programme against the draft ICH Q1, prepare protocols and justifications, and plan how new expectations will affect submissions and post-approval changes.

Contact PQRA to discuss your stability and regulatory strategy

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *